Amine compound and use thereof

Details Amine compound and use thereof Amine compound and use thereof

2007-02-09

2010-11-16

Fetterolf, Brandon J (Department: 1628)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Pyrethrum plant derived material or plant derived rotenone...

C548S312700, C514S397000

Reexamination Certificate

active

07833991

ABSTRACT:
It is intended to provide novel amine compounds which are efficacious against diseases such as infection with HIV virus, rheumatism and cancer metastasis. Namely, amine compounds represented by the following general formula (1):In a typical case, A1 and A2 represent each an optionally substituted monocyclic or polycyclic aromatic heterocycle; W represents cyclic C3-10 alkylene, an optionally substituted monocyclic or polycyclic aromatic heterocycle, a monocyclic or polycyclic aromatic ring or a partly saturated polycyclic aromatic ring; X represents O, CH2, C(═O) or NR11; and D is a group represented by the following general formula (4) or (6).In the formula (6), Q represents a single bond, S, O or NR12; and Y is a group represented by the following general formula (7).z represents an optionally substituted monocyclic or polycyclic aromatic ring. In the formula (6), B represents NR25R26. In the above formulae, R1 to R26 each represents hydrogen, alkyl, alkenyl or alkynyl.

REFERENCES:
patent: 3634316 (1972-01-01), Ito et al.
patent: 5086069 (1992-02-01), Klein et al.
patent: 5633231 (1997-05-01), Habich et al.
patent: 5886044 (1999-03-01), Widdowson et al.
patent: 6077954 (2000-06-01), Cook et al.
patent: 6096773 (2000-08-01), Scott et al.
patent: 6197965 (2001-03-01), Cook et al.
patent: 6204294 (2001-03-01), Bryan et al.
patent: 6329523 (2001-12-01), Cook et al.
patent: 6750348 (2004-06-01), Bridger et al.
patent: 7091217 (2006-08-01), Bridger et al.
patent: 7098215 (2006-08-01), Yamazaki et al.
patent: 7176227 (2007-02-01), Yamazaki et al.
patent: 2004/0157818 (2004-08-01), Yanaka et al.
patent: 2004/0171638 (2004-09-01), Bridger et al.
patent: 2004/0254221 (2004-12-01), Yamazaki et al.
patent: 2005/0165063 (2005-07-01), Yamazaki et al.
patent: 2006/0128750 (2006-06-01), Bridger et al.
patent: 2006/0264434 (2006-11-01), Bridger et al.
patent: 2007/0208007 (2007-09-01), Saitou et al.
patent: 0 183 271 (1986-06-01), None
patent: 0 628 551 (1994-12-01), None
patent: 0 646 598 (1995-04-01), None
patent: 1 389 460 (2004-02-01), None
patent: 1268419 (1972-03-01), None
patent: 7-89988 (1995-04-01), None
patent: 98/05961 (1998-02-01), None
patent: WO 98/06397 (1998-02-01), None
patent: WO 99/33787 (1999-07-01), None
patent: 00/06086 (2000-02-01), None
patent: WO 00/06086 (2000-02-01), None
patent: 00/56729 (2000-09-01), None
patent: WO 00/56729 (2000-09-01), None
patent: WO 01/10842 (2001-02-01), None
patent: WO 01/79168 (2001-10-01), None
patent: 02/22600 (2002-03-01), None
patent: WO 02/22600 (2002-03-01), None
patent: WO 02/94261 (2002-05-01), None
patent: 02/49993 (2002-06-01), None
patent: 02/062766 (2002-08-01), None
patent: WO 03/029218 (2003-04-01), None
patent: 2004/024697 (2004-03-01), None
patent: WO 2005/085209 (2005-10-01), None
Stella et al (Prodrugs: Challenges and Rewards, Part 1, 2007).
Williams et al (Foye's Principles of Medicinal Chemistry, 5th Ed., 2002).
Patani et al (Chem Rev 96:3147-3176, 1996).
U.S. Appl. No. 10/591,722, filed Sep. 5, 2006, Saitou et al.
Molino, M. et al., “CXCR4 on human endothelial cells can serve as both a mediator of biological responses and as a receptor for HIV-2,” Biochimica et Biophysica Acta (BBA), Molecular Basis of Disease, vol. 1500, Issue 2, Feb. 21, 2000, p. 227-240.
Database Caplus Chemical Abstract Service, XP00255118, Abstract of JP 11-269146.
Database Caplus Chemical Abstract Service, XP00255119, Abstract of JP 52-059794.
Supplementary European Search Report dated Nov. 27, 2009 that issued with respect to patent family member European Patent Application No. 03795301.5.
Saishin Igaku, vol. 53, No. 9, pp. 2031-2038 (1998) with English translation of abstract, Abstract Only.
Nikkei Science, Oct., p. 26-37 (1998) with English version Bartlett, John G. et al, “Improving HIV Therapy,” Scientific American, pp. 84-89 (Jul. 1998).
Molecular Medicine, vol. 36, No. 9, pp. 1012-1017 (1999) with English translation of abstract.
Nikkei Science, Oct., pp. 42-49 (1998) with English version Baltimore, David et al, “HIV Vaccines: Prospects and Challenges,” Scientific American, pp. 78-83 (Jul. 1998).
Feng, Yu et al, “HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor,” Science, 272, 872-877 (1996).
Bleul, Conrad C. et al, “The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry,” Nature, 382, 829-831 (1996).
Schols, Dominique et al, “Inhibition of T-tropic HIV Strains by Selective Antagonization of the Chemokine Receptor CXCR4,” J. Exp. Med., 186, 1383-1387 (1997).
Murakami, Tsutomu et al, “A Small Molecule CXCR4 Inhibitor that Blocks T Cell Line-tropic HIV-1 Infection,” J. Exp. Med., 186, 1389-1393 (1997).
Doranz, Benjamin J. et al, “A Small-molecule Inhibitor Directed against the Chemokine Receptor CXCR4 Prevents its Use as an HIV-1 Coreceptor,” J. Exp. Med., 186, 1395-1400 (1997).
Muller, Anja et al, “Involvement of chemokine receptors in breast cancer metastasis,” Nature, 410, 50-56 (2001).
Stella, Valentino J., Expert opinion of Therapeutic Patents, Prodrugs as therapeutics, 2004 14(3): 277-280.
Wolff et al (Burger's Medicinal Chemistry, 5thEd., Col. 1, pp. 975-977, 1994.
Testa, Bernard, Biochemical Pharmacology, Prodrug Research: futile or fertile? 68 (2004) 2097-2106.
Ettmayer, Peter, Medicinal Chemistry, Lessons Learned from Marketed and Investigational Prodrugs, 47(10) (2004) 2394-2404.

Affiliated with

Also associated with

Rating

Amine compound and use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Amine compound and use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Amine compound and use thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4241627